Skip to main content
MedPathMedPath Home
Clinical Trials/PER-143-08
PER-143-08
Completed
未知

A Phase II Study of Cyclosporine in the Treatment of Angioimmunoblastic T-Cell Lymphoma

EASTERN COOPERATIVE ONCOLOGY GROUP (ECOG),0 sites0 target enrollmentMarch 9, 2009
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
EASTERN COOPERATIVE ONCOLOGY GROUP (ECOG),
Status
Completed
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 9, 2009
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
EASTERN COOPERATIVE ONCOLOGY GROUP (ECOG),

Eligibility Criteria

Inclusion Criteria

  • •Diagnosis of angioimmunoblastic T\-cell lymphoma (recurrent or refractory) based on histologic examination.
  • •At least one objective measurable or evaluable disease parameter.
  • •Have failed at least one type of treatment: chemotherapy, auto\-transplant, or steroid treatment. Patients may not receive concurrent chemotherapy.
  • •Eastern Cooperative Oncology Group (ECOG) performance status of 0\-2\.
  • •Adequate renal function as indicated by creatinine \<\= 1\.5 the upper limit of normal (ULN).
  • •Adequate liver function as indicated by alkaline phosphatase, Aspartate Aminotransferase (AST), and Alanine Aminotransferase (ALT) \<\= 2x the upper limit of normal.
  • •Total bilirubin \<\= 2x the upper limit of normal.
  • •Age 18 or older.

Exclusion Criteria

  • •Prior cyclosporine or Tacrolimus (FK506\).
  • •Prior allogeneic transplant.
  • •Evidence of active infection.
  • •Congestive heart failure, kidney failure, liver failure, or other severe co\-morbidities.
  • •Evidence of active neurological impairment.
  • •Previous history of hypersensitivity to cyclosporine and/or Cremorphor EL (polyoxyethylated oil).
  • •History of other malignancies (other than cured carcinomas in situ of the cervix or basal cell carcinoma of the skin).
  • •pregnant or breastfeeding women.
  • •Human immunodeficiency virus (HIV) positive.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Withdrawn
Phase 3
A Phase III Study Comparing Low Dose Cyclosporine, Methotrexate And Prednisone Versus Standard Dose Cyclosporine and Methotrexate As Graft Versus Host Disease Prophylaxis In Myeloblative Allogeneic Stem Cell Transplantation (ALLG BM10 trial).(Incorporating an Open-Label Sub-study Investigating The Use Of Valganciclovir In The Prevention Of Cytomegalovirus Infection In Hematopoietic Stem Cell Transplant Recipients (ML20712))
ACTRN12607000347460Australasian Leukaemia and Lymphoma Group300
Active, not recruiting
Phase 1
An early phase trial of Cyclosporin A in patients with early stage Chronic Lymphocytic Leukaemia (CLL) who do not currently require treatment.
EUCTR2012-002795-13-GBniversity of Birmingham5
Completed
Not Applicable
A phase II trial of Cyclosporin A in early adverse risk Chronic Lymphocytic Leukaemia (CLL)Topic: National Cancer Research NetworkSubtopic: Haematological OncologyDisease: Leukaemia (chronic)CancerChronic lymphocytic leukaemia of B-cell type
ISRCTN61297219niversity of Birmingham (UK)5
Completed
Not Applicable
Efficacy of cyclosporine therapy in the treatment of non-severe aplastic anemiaaplastic anemia
JPRN-UMIN000030453Cooperative study between the West Japan Hematology Study Group and Clinical Research Support Center Kyushu34
Completed
Phase 4
Randomized prospective trial of cyclosporine with/without low-dose prednisolone in idiopathic membranous nephropathy in adults with nephrotic syndrome
ACTRN12609000996268Research Group for Treatments of Kidney Diseases in Ibaraki, Japan30